Efficacy and Safety of Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3, a Phase 3, Randomized Double-Blind Study

By sjmartinez • May 18, 2025

Eichenfield LF, Stein Gold LF, Simpson EL, Zaenglein AL, Armstrong AW, Tollefson MM, Soong W, Lee LW, Devani AR, Forman SB, Siri DD, Kallender H, Angel B, Li Q, Chen X, Paller AS. Efficacy and Safety of Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From TRuE-AD3, a Phase 3, Randomized Double-Blind Study. J Am Acad Dermatol. 2025 May 14:S0190-9622(25)02124-3. doi: 10.1016/j.jaad.2025.05.1385. Epub ahead of print. PMID: 40378883.

Tags: atopic dermatitis, children, Dermatology, eczema, efficacy, JAK inhibitor, Janus kinase, pediatric, phase 3, Publications, randomized, ruxolitinib cream, safety, topical

Reply to Botto et al’s “Applicant interview metrics and preference signaling in dermatology: A serial cross-sectional study”

Fleshner L, Chan R, Klufas T, Grant-Kels JM, Zhou AE. Reply to Botto et al's "Applicant interview metrics and preference signaling in dermatology: A serial[...]

Identification of a spatially organized TREM2-associated permissive macrophage niche in human pulmonary tuberculosis alveolar pneumonia

Teles RMB, Benabdessalem C, Perrie J, Wei C, West J, de Andrade Silva BJ, Andrade PR, Mansky LA, Divaka P, Fischbacher L, Lam K, Ma[...]

The State of Mohs Micrographic Surgery in 2025-2026: Current Challenges, Pressures, and the Path Forward

Zhou AE, Gronbeck C, Kim JJ, Yu S, Feng H, Klufas DM. The State of Mohs Micrographic Surgery in 2025-2026: Current Challenges, Pressures, and the[...]